Patent details

301371 Product Name: zuranolon en farmaceutisch aanvaardbare zouten daarvan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301371
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2986623
Status:
Application Pending
Application number:
301371
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/25/1977
Marketing Authorization Type:
EEA
Marketing Authorization Date:
18/09/2025
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
10/03/2026
First Marketing Authorization date:
18/09/2025
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
11/03/2026
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
10/03/2026
 
 

 

Name:
Sage Therapeutics, LLC
Address:
9715 Key West Avenue, 20850, Rockville, Maryland, United States of America (US)

Agent

Name:
ir. B.Ch. Ledeboer c.s
From:
10/03/2026
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
11/26
Publication date:
18/03/2026
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
31/03/2026 Outgoing Correspondence Letter to applicant 2 PDF /6/4/4/3/2/0801223446/docs/301371_9_301371702380l173.pdf
11/03/2026 Outgoing Correspondence Confirmation receipt request 2 PDF /6/4/4/3/2/0801223446/docs/301371_0_301371699584l174.pdf
10/03/2026 SPC Documents Accompanying letter SPC 3 PDF /6/4/4/3/2/0801223446/docs/301371_1_supplprotectioncertificate20260311122358878.pdf
10/03/2026 SPC Documents Summary of the characteristics of the product 14 PDF /6/4/4/3/2/0801223446/docs/301371_2_supplprotectioncertificate20260311122358894.pdf
10/03/2026 SPC Documents Annex SPC 2 PDF /6/4/4/3/2/0801223446/docs/301371_3_supplprotectioncertificate20260311122358902.pdf
10/03/2026 SPC Documents Annex SPC 3 PDF /6/4/4/3/2/0801223446/docs/301371_4_supplprotectioncertificate20260311122358925.pdf
10/03/2026 SPC Documents Annex SPC 32 PDF /6/4/4/3/2/0801223446/docs/301371_5_supplprotectioncertificate20260311122358915.pdf
10/03/2026 SPC Documents Annex SPC 8 PDF /6/4/4/3/2/0801223446/docs/301371_6_supplprotectioncertificate20260311122358937.pdf
10/03/2026 Application Form First filed application form 3 PDF /6/4/4/3/2/0801223446/docs/301371_7_applicationform20260311122358843.pdf
10/03/2026 SPC Documents Marketing Authorization SPC 3 PDF /6/4/4/3/2/0801223446/docs/301371_8_supplprotectioncertificate20260311122358886.pdf